NCT02842749 2025-02-10
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Novartis
Phase 4 Completed
Clinical Trials
10 trialsNCT03525834 2021-09-09
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Novartis
Phase 4 Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT01743560 2019-07-18
4EVERUK
Novartis
Phase 4 Completed
NCT01206764 2019-06-24
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Novartis
Phase 4 Completed
NCT01595009 2018-11-29
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
Novartis
Phase 4 Completed
NCT01266837 2017-11-14
MARC-2
iOMEDICO AG
Phase 4 Completed
NCT02248571 2017-11-13
IMPROVE
iOMEDICO AG
Phase 4 Completed
NCT01514448 2017-07-19
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Novartis
Phase 4 Completed
NCT02056587 2014-02-06
Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
Kidney Cancer Research Bureau
Phase 4 Completed